Replies to post #89942 on Biotech Values

[DewDiligence]

You’re probably right that the “third” ABT drug is ABT-072; however, the only phase-2 trial relating to ABT-072 listed at clinicaltrials.gov is this one, which does not exactly sound promising vis-à-vis continued development:

http://clinicaltrials.gov/ct2/show/NCT00872196

Moreover, to my knowledge, ABT has not mentioned ABT-072 by name in any press release for almost a year (i.e. since #msg-35708745). That’s why I wasn’t sure.